drugset / Trial / NCT03527732

Efficacy and Safety of IVM/ALB Co-administration

NCT03527732

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a double-blind randomized clinical trial conducted with two settings in Africa and one in Asia, namely Côte d'Ivoire, Pemba (Zanzibar, Tanzania) and Lao PDR. This study aims at providing evidence on the efficacy and safety of co-administered albendazole and ivermectin versus albendazole monotherapy (standard of care) against whipworm (T. trichiura) infections in children and adults (6-60 years). The efficacy of the treatment and potential extended effects on follow-up prevalence will be determined 14-21 days, 6 months and 12 months post-treatment by collecting another two stool samples. The cure rate will be calculated as the percentage of egg-positive subjects at baseline who become egg-negative after treatment.

Timeline

Start
2018-09-09
Primary completion
2020-05-15
Completion
2020-07-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Albendazole Small molecule 400 mg Oral
Subject Ivermectin Small molecule 200 ug/kg Oral
Subject Ivermectin Small molecule 400 ug/kg Oral
Subject Ivermectin Small molecule 600 ug/kg Oral

Indications